Trial · NCT07898007
Trial Comparing miLOOP Device Assisted Phacoemulsification vs Standard Surgery for Dense Cataracts: Effects on Endothelial Cell Loss, Energy Use, and Vision Recovery
NCT07898007, Not applicable, Recruiting, Universiti Kebangsaan Malaysia Medical Centre
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Trial Comparing miLOOP Device Assisted Phacoemulsification vs Standard Surgery for Dense Cataracts: Effects on Endothelial Cell Loss, Energy Use, and Vision Recovery. Trials, record NCT07898007. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07898007
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Trial Comparing miLOOP Device Assisted Phacoemulsification vs Standard Surgery for Dense Cataracts: Effects on Endothelial Cell Loss, Energy Use, and Vision Recovery
- NCT number
- NCT07898007
- Status
- Recruiting
- Phases
- Not applicable
- Enrollment
- 68 participants, estimated
- Lead sponsor
- Universiti Kebangsaan Malaysia Medical Centre
- Conditions
- Cataract, Endothelial Cell Density, Cumulative Dispersive Energy
- Interventions
The miLOOP utilizes a nickel-titanium (nitinol) loop to ensnare and exert centripetal cutting forces on the lens nucleus with decreasing loop diameter, Conventional phacoemulsification cataract surgery
- First posted
- 2026-10-27
- Last updated
- 2026-10-27
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Endothelial Cell Loss | Baseline, 1 month post-operatively, and 3 months post-operatively | Percentage change in corneal endothelial cell density (ECD) from baseline to 1month and 3 months postoperatively, comparing the miLOOP-assisted phacoemulsification group with the conventional phacoemulsification group. |
| Primary | Endothelial Cell Loss | Baseline, 1 month, and 3 months postoperatively | Percentage change in corneal endothelial cell density (ECD) from baseline to 1 month and 3 months postoperatively, comparing the miLOOP-assisted phacoemulsification group with the conventional phacoemulsification group. |
| Secondary | Cumulative dissipated energy | Intra-operatively | Comparison of cumulative dissipated energy recorded during phacoemulsification between the miLOOP-assisted and conventional phacoemulsification groups. |
| Secondary | Best-corrected visual acuity (BCVA) | Baseline, postoperative day 1, day 7, 1 month and 3 months | To compare post-operative visual outcomes in standard phaco-emulsification and miLOOP-assisted phacoemulsification for advanced visually significant cataract. |
| Secondary | Safety Outcomes | Intraoperative, Post-operative Day1, Day 7, 1 month, and 3 months | To compare the intra-operative and post-operative safety outcomes in standard phaco-emulsification and miLOOP-assisted phacoemulsification for advanced visually significant cataract. |
| Secondary | Anterior Capsular Contraction | 3 months post-operatively | To compare the degree of anterior capsular contraction following standard phacoemulsification and miLOOP-assisted phacoemulsification for advanced visually significant cataract |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07898007
GET https://conductscience.org/api/trials/v1/NCT07898007/registered